Parents say son with autism was nonverbal until trying an off-label drug that treats chemo side effects

Caroline Connor’s concerns about her son Mason’s development started when he turned one and showed no signs of talking or using words. Despite reassurances from their pediatrician, Mason’s speech delay persisted, leading to a diagnosis of autism at the age of 2 and a half.

The Connors embarked on a quest to find solutions to help Mason. Through their research, they discovered Dr. Richard Frye, a pediatric neurologist conducting studies on treatments for children with autism. One of the treatments being studied is leucovorin, a drug derived from folic acid known for its use in easing the side effects of cancer chemotherapy. Leucovorin has shown promising results in improving speech and behavior in children with autism.

Recently, the Food and Drug Administration (FDA) initiated the process of approving leucovorin as a treatment for autism, despite the lack of large-scale clinical trials. Dr. Frye acknowledges the need for more research to determine the correct dosage, timing, and which children will benefit most from the treatment.

The scientific basis for using leucovorin in autism revolves around the concept of cerebral folate deficiency (CFD), where there is a lack of folate in the brain. Studies have shown that children with autism may have autoantibodies against the folate receptor alpha (FR⍺), hindering the transport of folic acid into the brain. Leucovorin can bypass this blockage and improve folate levels in the brain, leading to enhancements in speech and behavior.

Despite the positive outcomes observed in studies, Dr. Frye expresses disappointment in the lack of funding for further research and the absence of his input in upcoming trials. He emphasizes the importance of identifying biomarkers to predict which children will respond best to leucovorin treatment.

Mason Connor’s parents attest to the transformative effects of leucovorin on their son, with his first words emerging shortly after starting the treatment. Although leucovorin is currently prescribed off-label for autism, efforts are underway to secure FDA approval for its use in this population.

Challenges exist in ensuring a consistent and high-quality supply of leucovorin, as different formulations may have varying tolerability. Dr. Frye is working on establishing a reliable source of leucovorin tailored for children with autism.

The story of Mason’s progress serves as a beacon of hope for families navigating autism, highlighting the potential of repurposed drugs like leucovorin to make a significant impact. As research continues and awareness grows, there is optimism for the future of treating autism with innovative solutions like leucovorin.